Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAC, tigecycline, and heparin lock solution for hemodialysis catheter-associated bacteremia
NCT01483872Phase 3
Key facts
- Status
- Terminated
- Start
- Mar 2012
- Primary completion
- Sep 2013
- Countries
- 1
- Sponsor
- University of California, San Diego
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands
- Conditions
- Bacteremia
01
Overview
Phase 3, randomised, double-blind trial of acetylcysteine, tigecycline and heparin in Bacteremia, sponsored by University of California, San Diego. Primary endpoint: Success Rate at 90 days. Started Mar 2012; status: terminated.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Adults with ESRD and a tunneled hemodialysis catheter experiencing bacteremia, excluding those with complicated infections, exit site infections, or tigecycline-resistant organisms.
04
Endpoints
Primary
Success Rate
Beyond the preview
Go deeper on NCT01483872.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01483872.